Preclinical evaluation of antineoplastic activity of inhibitors of DNA methylation (5-aza-2′-deoxycytidine) and histone deacetylation (trichostatin A, depsipeptide) in combination against myeloid leukemic cells

Synergistic antineoplastic action of DNA

Synergistic antineoplastic action of DNA methylation inhibitor 5-AZA-2′-deoxycytidine and histone deacetylase inhibitor depsipeptide on human breast carcinoma cells

✍ Mélanie Primeau; Jacynthe Gagnon; Richard L. Momparler 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 French ⚖ 233 KB

## Abstract During tumorigenesis, cancer‐related genes can be silenced by aberrant DNA methylation and by changes in chromatin structure. It has been reported that 5‐aza‐2′‐deoxycytidine, a potent inhibitor of DNA methylation, in combination with histone deacetylase inhibitors, can produce a synerg